Organizing pneumonia as a side effect of ipilimumab treatment of melanoma

Chest

Volumn 143, Issue 3, 2013, Pages 858-861

  Barjaktarevic, Igor Z ^a   Qadir, Nida ^a   Suri, Anu ^b   Santamauro, Jean T ^b   Stover, Diane ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IPILIMUMAB; METHYLPREDNISOLONE;

ADULT; ARTICLE; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE SEVERITY; DYSPNEA; FEMALE; HUMAN; HUMAN TISSUE; HYPOXIA; MELANOMA; METASTASIS; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY FAILURE; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY;

EID: 84874994077     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1467     Document Type: Article

References (21)

1. Boasberg P, Hamid O, O'Day S. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade. Semin Oncol. 2010; 37 (5): 440-449.
2. Culver ME, Gatesman ML, Mancl EE, Lowe DK. Ipilimumab: a novel treatment for metastatic melanoma. Ann Pharmacother. 2011; 45 (4): 510-519.
3. Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009; 113 (7): 1581-1588.
4. Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009; 15 (20): 6446-6453.
5. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 doseescalation trial. Lancet Oncol. 2012; 13 (5): 501-508.
6. van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castrationresistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012; 13 (5): 509-517.
7. Tomasini P, Khobta N, Greillier L, Barlesi F. Ipilimumab: its potential in non-small cell lung cancer. Ther Adv Med Oncol. 2012; 4 (2): 43-50.
8. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti- CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30 (8): 825-830.
9. Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005; 175 (11): 7746-7754.
10. Weber JS, Kähler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30 (21): 2691-2697.
11. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23 (25): 6043-6053.
12. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010; 37 (5): 499-507.
13. Kähler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges. 2011; 9 (4): 277-286.
14. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immunerelated colitis. Cancer Biother Radiopharm. 2009; 24 (3): 321-325.
15. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol. 2010; 21 (8): 1712-1717.
16. Mukae H, Kadota J, Kohno S, Matsukura S, Hara K. Increase of activated T-cells in BAL fluid of Japanese patients with bronchiolitis obliterans organizing pneumonia and chronic eosinophilic pneumonia. Chest. 1995; 108 (1): 123-128.
17. Costabel U, Teschler H, Guzman J. Bronchiolitis obliterans organizing pneumonia (BOOP): the cytological and immunocytological profile of bronchoalveolar lavage. Eur Respir J. 1992; 5 (7): 791-797.
18. Satake N, Nagai S, Kawatani A, et al. Density of phenotypic markers on BAL T-lymphocytes in hypersensitivity pneumonitis, pulmonary sarcoidosis and bronchiolitis obliterans with organizing pneumonia. Eur Respir J. 1993; 6 (4): 477-482.
19. Stanek EJ, Nelson CE, DeNofrio D. Amlodipine overdose. Ann Pharmacother. 1997; 31 (7-8): 853-856.
20. Kelly CA, Upex A, Spencer EP, Flanagan RJ, Bateman DN. Adult respiratory distress syndrome and renal failure associated with citalopram overdose. Hum Exp Toxicol. 2003; 22 (2): 103-105.
21. Mecca P, Tobin E, Andrew Carlson J. Photo-distributed neutrophilic drug eruption and adult respiratory distress syndrome associated with antidepressant therapy. J Cutan Pathol. 2004; 31 (2): 189-194.